Speeding development of poorly soluble/poorly permeable drugs by SEDDS/S-SEDDS formulations and prodrugs (part II)

American Pharmaceutical Review

Volumn 9, Issue 3, 2006, Pages 16-23

  Gao, Ping ^a   Charton, Marvin ^b   Morzowich, Walt ^c  

^a AMGEN INC   (United States)

^b PRATT INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; CORTICOTROPIN RELEASING FACTOR; CYCLOSPORIN A; GABAPENTIN; LATANOPROST; MELAGATRONE; OSELTAMIVIR; PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG; XIMELAGATRAN;

COLITIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; INTESTINE ABSORPTION; NONHUMAN; REVIEW;

EID: 55749087200     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Gao, P., Morozowich, W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Expert. Opin. Drug Deliv., 3(1), 97-110 (2006).
2. Gao, P., Morozowich, W. Selection of clinical SEDDS formulations based on interpretation of preformulation drug properties and preclinical pharmacokinetic performance, in "Lipid based formulations for oral drug delivery: Enhancing the bioavailability of poorly water-soluble drugs", ed. D.J.Hauss, (Marcell Dekker), publication date, 2005a.
3. Gao, P., W.Morozowich, W. Design and development of a new class of supersaturatable SEDDS with potential for enhanced oral absorption and reduced GI side effects, in Lipid based formulations for oral drug delivery: Enhancing the bioavailability of poorly water-soluble drugs, ed. D.J.Hauss, (Marcell Dekker), publication date, 2005b.
4. Gao, P., Rush, B,D,, Pfund, W.P., Huang, T., Bauer, J.M., Morozowich, W., Kuo, M.S., Hageman, M,J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci., 92(12), 2386-98 (2003).
5. Serajuddin, A.T.M., Jarowski, C.I. Effect of Diffusion Layer pH and Solubility on the Dissolution Rate of Pharmaceutical Bases and Their Hydrochloride Salts I. Phenylazopyridine. J. Pharm. Sci., 74(2), 142-7 (1985).
6. Paulson, S.K., Vaughn, M.B., Jessen, S.M., Lawal, Y., Gresk, C.J., Yan, B., Maziasz, T.J., Cook, C.C., Karim, A. Pharmacokinetics of Celecoxib after Oral Administration in Dogs and Humans: Effect of Food and Site of Absorption. J.Pharmacol.Exp.Therap., 297(2), 638-645 (2001).
7. Ho, N.H., Park, J.Y., Ni, P.F., Higuchi, W.I. Advancing quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and man, in Animal Models for Oral Drug Delivery in Man, in In Situ and In Vivo Approaches (Crouthamel, W.G. and Sarapu ,A. eds.), AphA/APS, Washington, DC, pp 27-106 (1983).
8. Fichert T, Yazdanian M, Proudfoot JR. A structure-permeability study of small drug-like molecules. Bioorg. Med. Chem. Lett., 13, 719-722 (2003).
9. Camenisch, G., Folkers, G., van de Waterbeemd, H. Shapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. Eur J Pharm Sci. 6(4), 325-29 (1998).
10. Sloan, K.B., Wasdo, S. Designing for topical delivery: prodrugs can make the difference. Med. Res. Rev., 23, 763-793 (2003).
11. Testa, B., Mayer, J.M. Hydrolysis in Drug and Prodrug Metabolism : chemistry, biochemistry and enzymology. Wiley-VCH, Weinheim (2003).
12. Charton, M., Charton, B.I. Advances in Quantitative Structure- Property Relationschips. Vol. 3, Elsevier, Amsterdam (2002).
13. Buchwald P. Structure-metabolism relationships: steric effects and the enzymatic hydrolysis of carboxylic esters. Mini Rev. Med. Chem., 1(1), 101-11 (2001).
14. Buchwald P, Bodor N. Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J.Med.Chem., 16, 42(25), 5160-8 (1999).
15. Anderson, B.D., Conradi, R.A., Spilman, C.H., Forbes, A.D. Strategies in the design of solution-stable, water-soluble prodrugs III: influence of the pro-moiety on the bioconversion of 21-esters of corticosteroids. J. Pharm. Sci., 74(4), 382-7 (1985).
16. Gubareva, L.V., Kaiser, L., Hayden, F.G. Influenza virus neuraminidase inhibitors. The Lancet, 355, 827-835 (2000).
17. Eriksson, U.G., Bredberg, U., Hoffmann, K.J., Thuresson, A., Gabrielsson, M., Ericsson, H. Absorption, Distribution, Metabolism, and Excretion of Ximelagatran, an Oral Direct Thrombin Inhibitor, in Rats, Dogs, and Humans. Drug Metab Dispos., 31(3), 294-305 (2003).
18. Wolzt, M., Sarich, T.S., Eriksson, U.G. Pharmacokinetics and pharmacodynamics of ximelagatran. Semin. Vascul. Med., 5(3), 245- 253 (2005).
19. Cundy, K.C., Annamalai, T., Bu, L., De Vera, J., Estrela, J., Luo, W., Shirsat, P., Torneros, P., Yao, F., Zou, J., Barrett, R.W., Gallop, M.A. XP13512 [(±)-1-([(-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: II. Improved Oral Bioavailability, Dose Proportionality, and Colonic Absorption Compared with Gabapentin in Rats and Monkeys. J. Pharmacol. Exp.Therap., 311, 324-333 (2004).
20. Sjoquist, B., Stjernschantz, J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv. Ophthalmol., 47(Suppl 1), S6- S12 (2002).
21. Smith, D.A., van Waterbeemd, H., Walter, D.K. Pharmacokinetics and Metabolism in Drug Design. In, Methods and Principles in Medicinal Chemistry. Vol. 13, Wiley-VCH, Weinheim, p. 150-195 (2001).
22. Gao, P., Guyton, M.E., Huang, T., Bauer, J.M., Stefanski, K.J., Lu, Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by novel supersaturatable formulations. Drug Dev. Ind. Pharm., 30(2), 221-229 (2004).
23. Clement, B., Lopian, K. Characterization of In Vitro Biotransformation of New, Orally Active, Direct Thrombin Inhibitor Ximelagatran, an Amidoxime and Ester Prodrug. 31(5), 645-651 (2003).
24. Plaisance, K., Drusano, G.L., Forest, A., Towsend, R.J. Pharmacokinetic Evaluation of Two Dosage Regimens of Clindamycin